Spyre Therapeutics Inc. (NASDAQ: SYRE) completed enrollment for all sub-studies in its SKYWAY basket trial evaluating SPY072, an anti-TL1A antibody, for treatment of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

The company finished enrollment across all sub-studies in less than nine months. Spyre expects topline data for rheumatoid arthritis in the third quarter of 2026 and results for psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026.

The SKYWAY Phase 2 trial is a randomized, placebo-controlled study examining SPY072 in patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who had inadequate responses to conventional or advanced therapies.

SPY072 is an investigational antibody with extended half-life targeting TL1A, a cytokine involved in T-cell-driven inflammation. The therapy is designed for quarterly or twice-yearly subcutaneous maintenance dosing.

"Completing enrollment across all SKYWAY sub-studies in less than nine months underscores the substantial unmet need among the more than three million U.S. patients living with RA, PsA, and axSpA," said MiRa Huyghe, senior vice president of development operations.

Spyre stated it remains on track for five additional Phase 2 readouts in 2026 across its SKYWAY and SKYLINE trials. The company presented preclinical data supporting SPY072 efficacy in rheumatic diseases at the 2026 European Congress of Rheumatology.

The Waltham, Massachusetts-based clinical-stage biotechnology company focuses on developing extended half-life antibodies targeting immunological pathways.